{"id":524180,"date":"2021-08-05T09:03:52","date_gmt":"2021-08-05T13:03:52","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-second-quarter-2021-financial-results-and-recent-corporate-update-on-august-12\/"},"modified":"2021-08-05T09:03:52","modified_gmt":"2021-08-05T13:03:52","slug":"capricor-therapeutics-to-present-second-quarter-2021-financial-results-and-recent-corporate-update-on-august-12","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-second-quarter-2021-financial-results-and-recent-corporate-update-on-august-12\/","title":{"rendered":"Capricor Therapeutics to Present Second Quarter 2021 Financial Results and Recent Corporate Update on August 12"},"content":{"rendered":"<h2>\nCompany to Host Conference Call, August 12, 2021, at 4:30 p.m. ET<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"justify\">LOS ANGELES, Aug.  05, 2021  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VDKw70mOs1EZKclZS7xJoIMLe9n_0vb_zn2aGGd-XX7MbX5vmvkdiJ1V_f-l_G4QSuHEljTu2XMQA4E1rdz8nA==\" rel=\"nofollow noopener\" target=\"_blank\">Capricor Therapeutics<\/a> (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, will release its financial results for the second quarter ended June 30, 2021, after the market close on Thursday August 12, 2021. Management will then host a webcast and conference call at 4:30 p.m. ET on August 12.<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:20%;width:20%;min-width:20%;vertical-align: middle;text-align: left;padding-left: 25.0px;vertical-align: top\">\n            <strong>Title:<\/strong><br \/>\n            \n          <\/td>\n<td style=\"max-width:80%;width:80%;min-width:80%;vertical-align: middle;text-align: left;padding-left: 25.0px;vertical-align: top\">Capricor Therapeutics Second Quarter 2021 Financial Results and Recent Corporate Update Conference Call and Webcast<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 25.0px;vertical-align: top\">\n            <strong>Date:<\/strong>\n          <\/td>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 25.0px;vertical-align: middle\">Thursday, August 12, 2021<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 25.0px;vertical-align: top\">\n            <strong>Time:<\/strong>\n          <\/td>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 25.0px;vertical-align: middle\">4:30 p.m. ET<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 25.0px;vertical-align: middle\">\n            <strong>Conference Call<br \/>Details:<\/strong>\n          <\/td>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 25.0px;vertical-align: middle\">Toll-Free: 866-269-4264<br \/>International: 929-477-0577<br \/>Conference ID: 1169561<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 25.0px;vertical-align: middle\">\n            <strong>Webcast:<\/strong>\n          <\/td>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 25.0px;vertical-align: middle\">\n            <a href=\"http:\/\/public.viavid.com\/index.php?id=146080\" rel=\"nofollow noopener\" target=\"_blank\">http:\/\/public.viavid.com\/index.php?id=146080<\/a>\n          <\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the Company\u2019s website.<\/p>\n<p align=\"justify\">\n        <strong>About Capricor Therapeutics<\/strong>\n      <\/p>\n<p align=\"justify\">Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company focused on developing transformative cell- and exosome-based therapeutics and vaccines for treating and preventing a broad spectrum of diseases. Capricor&#8217;s lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy that is currently in clinical development for treating Duchenne muscular dystrophy and the cytokine storm associated with COVID-19. Capricor is also developing its exosome technology as a next-generation therapeutic platform. The Company\u2019s current focus is on developing exosomes loaded with nucleic acids, including mRNA, to treat or prevent a variety of diseases. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UvIZ5qB4gEnDr3CoYmJhCcmDJDhtW5uowh9KWOV2tgbmlZbE7VcgUA2fl7Dfj2GjY6wNYSwTHH-u6Jofuw8MWA==\" rel=\"nofollow noopener\" target=\"_blank\">www.capricor.com<\/a>, and follow the Company on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=H40mL1EQK2-oJvzdMkFATCf2o1MPPHQN9T1wDdUQyDOIOxwggxGwcw8d6Bw1eNkPVBIBJ85rXgKG-Uzl42PTTjN90W6pljI8heA6pHxQJnY=\" rel=\"nofollow noopener\" target=\"_blank\">Facebook<\/a>,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mIxde1eTRNpeHVByxOQdloxxWQDp7lI5wBjwKYhafypBV0PklRhmo3ZwisWX0ie2mqoxZ7KfRAqJfiKYVqJDW09tN1WK21hpL69HLZ_xw0M=\" rel=\"nofollow noopener\" target=\"_blank\">Instagram<\/a>\u00a0and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=BMK6gL6tHaylvPbQHdFM0KdGPu6d24Ud5AtdLZYAYbIPLsdPRZv3DtUc9K8TsrDm3IBLjKEwQWQpmGas72D6gw==\" rel=\"nofollow noopener\" target=\"_blank\">Twitter<\/a>.<\/p>\n<p>\n        <strong>Cautionary Note Regarding Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor&#8217;s product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including the ability to obtain regulatory approvals or otherwise bring products to market; plans regarding current and future collaborative activities and the ownership of commercial rights; scope, duration, validity and enforceability of intellectual property rights; future royalty streams, revenue projections; expectations with respect to the expected use of proceeds from the recently completed offerings and the anticipated effects of the offerings; and any other statements about Capricor&#8217;s management team&#8217;s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words &#8220;believes,&#8221; &#8220;plans,&#8221; &#8220;could,&#8221; &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;estimates,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor&#8217;s business is set forth in Capricor&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020 as filed with the Securities and Exchange Commission on March 15, 2021 and in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 as filed with the Securities and Exchange Commission on May 14, 2021. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.<\/p>\n<p align=\"justify\">\n        <em>CAP-1002 is an Investigational New Drug and is not approved for any indications. None of Capricor\u2019s exosome-based candidates have been approved for clinical investigation.<\/em>\n      <\/p>\n<p>\n        <strong>For more information, please contact:<\/strong>\n      <\/p>\n<p>\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Caitlin Kasunich \/ Raquel Cona<br \/>KCSA Strategic Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Y7Q45rEA1blTYX9Is2ctlctfi0Y0KSjtstanBRh-NI6z6-gYaHDRhjZiQ7OkPrgonFIj0WCWKeno8t_V9TzFoiUo_F5X-7Ndv9bXFtQyYXw=\" rel=\"nofollow noopener\" target=\"_blank\">ckasunich@kcsa.com<\/a>\u00a0\/\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=20PBVGaHESBOyWQH-S946GiEd9QV5s5viWkBeA3Eau0DODkZr6wgedhD7xx5qbpq52Ur2MUl6ZbRZd_D8WyZgg==\" rel=\"nofollow noopener\" target=\"_blank\">rcona@kcsa.com<\/a><br \/>212.896.1241 \/ 212.896.1204<\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Joyce Allaire<br \/>LifeSci Advisors, LLC<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6ciBHlXal7UcONIlbwtTEA1SYI6_GoQJOmFN_uvdUUaAyZUsMD2ke689kMKgomYqKjGKfeyZSc6_AuSXQjUd6QwUbbLOM_66EyqfFHKqX6cKkBqGkg-JTaSxttwqby0L\" rel=\"nofollow noopener\" target=\"_blank\">jallaire@lifesciadvisors.com<\/a><br \/>617.435.6602<\/p>\n<p>\n        <strong>Company Contact:<\/strong><br \/>\n        <br \/>AJ Bergmann, Chief Financial Officer<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=25q9oQBv0j5D5SFzM9cQA6u5gdcP_tOIhFq5Ze104JX53JUTwEUbw8JxQxYKOrLkuvNiDq-C_bpuYai6c-KsxLPC2B2np7uEdMEb0YxQ7sM=\" rel=\"nofollow noopener\" target=\"_blank\">abergmann@capricor.com<\/a><br \/>310.358.3200\u00a0<\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMzM1NCM0MzQyNzc4IzUwMDA2ODU2Ng==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/44fdc0a5-dcca-4ed9-a85d-2af11e6100d8\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Company to Host Conference Call, August 12, 2021, at 4:30 p.m. ET LOS ANGELES, Aug. 05, 2021 (GLOBE NEWSWIRE) &#8212; Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, will release its financial results for the second quarter ended June 30, 2021, after the market close on Thursday August 12, 2021. Management will then host a webcast and conference call at 4:30 p.m. ET on August 12. Title: Capricor Therapeutics Second Quarter 2021 Financial Results and Recent Corporate Update Conference Call and Webcast Date: Thursday, August 12, 2021 Time: 4:30 p.m. ET Conference CallDetails: Toll-Free: 866-269-4264International: 929-477-0577Conference ID: 1169561 Webcast: http:\/\/public.viavid.com\/index.php?id=146080 &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-second-quarter-2021-financial-results-and-recent-corporate-update-on-august-12\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Capricor Therapeutics to Present Second Quarter 2021 Financial Results and Recent Corporate Update on August 12&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-524180","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Capricor Therapeutics to Present Second Quarter 2021 Financial Results and Recent Corporate Update on August 12 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-second-quarter-2021-financial-results-and-recent-corporate-update-on-august-12\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Capricor Therapeutics to Present Second Quarter 2021 Financial Results and Recent Corporate Update on August 12 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Company to Host Conference Call, August 12, 2021, at 4:30 p.m. ET LOS ANGELES, Aug. 05, 2021 (GLOBE NEWSWIRE) &#8212; Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, will release its financial results for the second quarter ended June 30, 2021, after the market close on Thursday August 12, 2021. Management will then host a webcast and conference call at 4:30 p.m. ET on August 12. Title: Capricor Therapeutics Second Quarter 2021 Financial Results and Recent Corporate Update Conference Call and Webcast Date: Thursday, August 12, 2021 Time: 4:30 p.m. ET Conference CallDetails: Toll-Free: 866-269-4264International: 929-477-0577Conference ID: 1169561 Webcast: http:\/\/public.viavid.com\/index.php?id=146080 &hellip; Continue reading &quot;Capricor Therapeutics to Present Second Quarter 2021 Financial Results and Recent Corporate Update on August 12&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-second-quarter-2021-financial-results-and-recent-corporate-update-on-august-12\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-05T13:03:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMzM1NCM0MzQyNzc4IzUwMDA2ODU2Ng==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-to-present-second-quarter-2021-financial-results-and-recent-corporate-update-on-august-12\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-to-present-second-quarter-2021-financial-results-and-recent-corporate-update-on-august-12\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Capricor Therapeutics to Present Second Quarter 2021 Financial Results and Recent Corporate Update on August 12\",\"datePublished\":\"2021-08-05T13:03:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-to-present-second-quarter-2021-financial-results-and-recent-corporate-update-on-august-12\\\/\"},\"wordCount\":620,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-to-present-second-quarter-2021-financial-results-and-recent-corporate-update-on-august-12\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwMzM1NCM0MzQyNzc4IzUwMDA2ODU2Ng==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-to-present-second-quarter-2021-financial-results-and-recent-corporate-update-on-august-12\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-to-present-second-quarter-2021-financial-results-and-recent-corporate-update-on-august-12\\\/\",\"name\":\"Capricor Therapeutics to Present Second Quarter 2021 Financial Results and Recent Corporate Update on August 12 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-to-present-second-quarter-2021-financial-results-and-recent-corporate-update-on-august-12\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-to-present-second-quarter-2021-financial-results-and-recent-corporate-update-on-august-12\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwMzM1NCM0MzQyNzc4IzUwMDA2ODU2Ng==\",\"datePublished\":\"2021-08-05T13:03:52+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-to-present-second-quarter-2021-financial-results-and-recent-corporate-update-on-august-12\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-to-present-second-quarter-2021-financial-results-and-recent-corporate-update-on-august-12\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-to-present-second-quarter-2021-financial-results-and-recent-corporate-update-on-august-12\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwMzM1NCM0MzQyNzc4IzUwMDA2ODU2Ng==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwMzM1NCM0MzQyNzc4IzUwMDA2ODU2Ng==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-to-present-second-quarter-2021-financial-results-and-recent-corporate-update-on-august-12\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Capricor Therapeutics to Present Second Quarter 2021 Financial Results and Recent Corporate Update on August 12\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Capricor Therapeutics to Present Second Quarter 2021 Financial Results and Recent Corporate Update on August 12 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-second-quarter-2021-financial-results-and-recent-corporate-update-on-august-12\/","og_locale":"en_US","og_type":"article","og_title":"Capricor Therapeutics to Present Second Quarter 2021 Financial Results and Recent Corporate Update on August 12 - Market Newsdesk","og_description":"Company to Host Conference Call, August 12, 2021, at 4:30 p.m. ET LOS ANGELES, Aug. 05, 2021 (GLOBE NEWSWIRE) &#8212; Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, will release its financial results for the second quarter ended June 30, 2021, after the market close on Thursday August 12, 2021. Management will then host a webcast and conference call at 4:30 p.m. ET on August 12. Title: Capricor Therapeutics Second Quarter 2021 Financial Results and Recent Corporate Update Conference Call and Webcast Date: Thursday, August 12, 2021 Time: 4:30 p.m. ET Conference CallDetails: Toll-Free: 866-269-4264International: 929-477-0577Conference ID: 1169561 Webcast: http:\/\/public.viavid.com\/index.php?id=146080 &hellip; Continue reading \"Capricor Therapeutics to Present Second Quarter 2021 Financial Results and Recent Corporate Update on August 12\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-second-quarter-2021-financial-results-and-recent-corporate-update-on-august-12\/","og_site_name":"Market Newsdesk","article_published_time":"2021-08-05T13:03:52+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMzM1NCM0MzQyNzc4IzUwMDA2ODU2Ng==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-second-quarter-2021-financial-results-and-recent-corporate-update-on-august-12\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-second-quarter-2021-financial-results-and-recent-corporate-update-on-august-12\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Capricor Therapeutics to Present Second Quarter 2021 Financial Results and Recent Corporate Update on August 12","datePublished":"2021-08-05T13:03:52+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-second-quarter-2021-financial-results-and-recent-corporate-update-on-august-12\/"},"wordCount":620,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-second-quarter-2021-financial-results-and-recent-corporate-update-on-august-12\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMzM1NCM0MzQyNzc4IzUwMDA2ODU2Ng==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-second-quarter-2021-financial-results-and-recent-corporate-update-on-august-12\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-second-quarter-2021-financial-results-and-recent-corporate-update-on-august-12\/","name":"Capricor Therapeutics to Present Second Quarter 2021 Financial Results and Recent Corporate Update on August 12 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-second-quarter-2021-financial-results-and-recent-corporate-update-on-august-12\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-second-quarter-2021-financial-results-and-recent-corporate-update-on-august-12\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMzM1NCM0MzQyNzc4IzUwMDA2ODU2Ng==","datePublished":"2021-08-05T13:03:52+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-second-quarter-2021-financial-results-and-recent-corporate-update-on-august-12\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-second-quarter-2021-financial-results-and-recent-corporate-update-on-august-12\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-second-quarter-2021-financial-results-and-recent-corporate-update-on-august-12\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMzM1NCM0MzQyNzc4IzUwMDA2ODU2Ng==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMzM1NCM0MzQyNzc4IzUwMDA2ODU2Ng=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-second-quarter-2021-financial-results-and-recent-corporate-update-on-august-12\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Capricor Therapeutics to Present Second Quarter 2021 Financial Results and Recent Corporate Update on August 12"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/524180","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=524180"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/524180\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=524180"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=524180"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=524180"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}